Advertisement

Spezielle Aspekte bezogen auf Organsysteme nach geriatrisch klinischer Bedeutung

  • Martin Wehling
  • Heinrich Burkhardt
  • Stefan Schwarz
  • Lutz Frölich
  • Ulrich Wedding
Chapter
  • 472 Downloads

Zusammenfassung

Die arterielle Hypertonie ist die häufigste Herz-Kreislauf-Erkrankung überhaupt, und sie ist eine Alterskrankheit. In den westlichen Industrienationen sind die älteren Menschen (>65 Jahre) die am stärksten wachsende Bevölkerungsgruppe.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Alderman MH (1999) A new model of risk: implications of increasing pulse pressure and systolic blood pressure on cardiovascular disease. J Hypertens Suppl 17(5):S25–S28PubMedGoogle Scholar
  2. Deutsche Hochdruckliga (DHL) (2006) AWMF-Leitlinie arterielle Hypertonie 2003–2008. http://www.uni-duesseldorf.de/AWMF/ll/046-001.htm. Gesehen 5.7.2008Google Scholar
  3. Beckett NS, Peters R, Fletcher AE et al. (2008) Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358:1887–1898PubMedCrossRefGoogle Scholar
  4. Boersma E, Keil U, De Bacquer D et al. (2003) Blood pressure is insufficiently controlled in European patients with established coronary heart disease. J Hypertens 21:1831–1840PubMedCrossRefGoogle Scholar
  5. Conlin PR, Gerth WC, Fox J, Roehm JB, Boccuzzi SJ (2001) Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes. Clin Ther 23:1999–2010PubMedCrossRefGoogle Scholar
  6. Düsing R (2001) Adverse events, compliance, and changes in therapy. Curr Hypertens Rep 3:488–492PubMedCrossRefGoogle Scholar
  7. Hasford J, Schröder-Bernhardi D, Rottenkolber M, Kostev K, Dietlein G (2000) Persistence with antihypertensive treatments: results of a 3-year follow-up cohort study. Eur J Clin Pharmacol 63:1055–1061CrossRefGoogle Scholar
  8. Hense HW (2000) MONICA Study: Epidemiology of arterial hypertension and implications for its prevention. 10-year results of the MONICA Study Augsburg). Dtsch Med Wochenschr 125:1397–1402PubMedCrossRefGoogle Scholar
  9. Insua JT, Sacks HS, Lau TS, Lau J, Reitman D, Pagano D, Chalmers TC (1994) Drug treatment of hypertension in the elderly: a meta-analysis. Ann Intern Med 121(5):355–362PubMedGoogle Scholar
  10. Lawes C, Vander Hoorn S, Rodgers A (2008) for the International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet 371:1513–1518PubMedCrossRefGoogle Scholar
  11. Löwel H, Kuch B, Meisinger C, Müller J, Hörmann A (2001) Koronarpatient im Alter — epidemiologische Sicht. Herzmedizin 18:110–119Google Scholar
  12. Mancia G, De Backer G, Dominiczak A et al. (2007) Guidelines for the management of arterial Hypertension. Eur Heart J 28:1462–1536PubMedGoogle Scholar
  13. Milchak JL, Carter BL, Ardery G, Dawson JD, Harmston M, Franciscus CL (2008) Physician adherence to blood pressure guidelines and its effect on seniors. Pharmacotherapy 28(7):843–851PubMedCrossRefGoogle Scholar
  14. Plouin PF, Rossignol P, Bobrie G (2006) Hypertension in the elderly. Bull Acad Natl Med 190:793–805PubMedGoogle Scholar
  15. Sagie A, Larson MG, Levy D (1993) The natural history of borderline isolated systolic hypertension. N Engl J Med 329(26):1912–1917PubMedCrossRefGoogle Scholar
  16. Staessen JA, Thijs L, Fagard R et al. (1999) Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA 282:539–546PubMedCrossRefGoogle Scholar
  17. Sytkowski PA, D’Agostino RB, Belanger AJ, Kannel WB (1996) Secular trends in long-term sustained hypertension, long-term treatment, and cardiovascular mortality. The Framingham Heart Study 1950 to 1990. Circulation 93:697–703PubMedGoogle Scholar
  18. Wittchen HU, Glaesmer H, März W (2005) Cardiovascular risk factors in primary care: methods and baseline prevalence rates — the DETECT program. Curr Med Res Opin 21:619–630PubMedCrossRefGoogle Scholar

Literatur

  1. Ahmed A, Husain A, Love TE, et al. (2006) Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J 27:1431–1439PubMedCrossRefGoogle Scholar
  2. Arzneimittelkommission der deutschen ärzteschaft (2007) Chronische Herzinsuffizienz. Arzneiverordnung in der Praxis, Bd 34, Sonderheft 3 (Therapieempfehlungen), April 2007, http://www.akdae.de/en/35/65-Herzinsuffizienz-2007-3Auflage.pdf. Gesehen 6.4.09Google Scholar
  3. Brunner-La Rocca HP, Buser PT, Schindler R, Bernheim A, Rickenbacher P, Pfisterer M; TIME-CHF-Investigators (2006) Management of elderly patients with congestive heart failure — design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Am Heart J 151(5):949–955PubMedCrossRefGoogle Scholar
  4. Bulpitt CJ (2005) Secondary prevention of coronary heart disease in the elderly. Heart 91:396–400PubMedCrossRefGoogle Scholar
  5. Cowie MR, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Suresh V, Sutton GC (1999) Incidence and aetiology of heart failure; a population-based study. Eur Heart J 20(6):421–428PubMedCrossRefGoogle Scholar
  6. Deedwania PC, Gottlieb S, Ghali JK, et al. (2004) Efficacy, safety and tolerability of beta-adrenergic blockade with metoprolol XL in elderly patients with heart failure. Eur Heart J 25:1300–1309PubMedCrossRefGoogle Scholar
  7. Flather MD, Yusuf S, Kober L, et al. (2000) Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 355:1575–1581PubMedCrossRefGoogle Scholar
  8. Flather MD, Shibata MC, Coats AJ et al. (2005) Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26(3):215–225PubMedCrossRefGoogle Scholar
  9. Ho KKL, Pinsky JL, Kannel WB, Levy D (1993) The epidemiology of heart failure — the Framingham Study. J Am Coll Cardiol 22:A6–A13CrossRefGoogle Scholar
  10. Hunt SA, Abraham WT, Chin MH, et al. (2005) ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Writing Committee to update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112: e154–e235PubMedCrossRefGoogle Scholar
  11. Kannel WB, Belanger AJ (1991) Epidemiology of heart failure. Am Heart J 121:951–957PubMedCrossRefGoogle Scholar
  12. Leibundgut G von, Pfisterer M, Brunner-La Rocca HP (2007) Drug treatment of chronic heart failure in the elderly. Drugs Aging 24(12):991–1006PubMedCrossRefGoogle Scholar
  13. Zuccalà G, Onder G, Marzetti E et al. (2005) Use of angiotensin-converting enzyme inhibitors and variations in cognitive performance among patients with heart failure. Eur Heart J 26(3):226–233PubMedCrossRefGoogle Scholar

Literatur

  1. Adams HP Jr, del Zoppo G, Alberts MJ et al. (2007) Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 38(5):1655–1711PubMedCrossRefGoogle Scholar
  2. Adams RJ, Albers G, Alberts MJ et al. (2008) Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 39(5):1647–1652PubMedCrossRefGoogle Scholar
  3. Amarenco P, Bogousslavsky J, Callahan A 3rd et al. (2006) High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355:549–559PubMedCrossRefGoogle Scholar
  4. Aronow WS, Ahn C (1996) Risk factors for new coronary events in a large cohort of very elderly patients with and without coronary artery disease. Am J Cardiol 77:864–866PubMedCrossRefGoogle Scholar
  5. Bach RG, Cannon CP, Weintraub WS et al. (2005) The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes. Ann Intern Med 141(3):186–195Google Scholar
  6. Baigent C, Keech A, Kearney PM et al. (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493):1267–1278PubMedCrossRefGoogle Scholar
  7. Boersma E, Harrington RA, Moliterno DJ et al. (2002) Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 359(9302):189–198PubMedCrossRefGoogle Scholar
  8. COMMIT Collaborative Group (2005) Early intravenous then oral metoprolol in 45852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 366:1622–1632CrossRefGoogle Scholar
  9. Döser S, März W, Reinecke MF et al. (2004) Empfehlungen zur Statintherapie im Alter: Daten und Consensus. Internist (Berl) 45(9):1053–1062CrossRefGoogle Scholar
  10. Gesundheitsberichterstattung des Bundes (2009) Daten zu Herzinfarkten in der Region Augsburg. Mortalität, Morbidität, Letalität, Vorerkrankungen, medizinische Versorgung. http://www.gbe-bund.de/gbe10/ergebnisse.prc_tab?fid=6770&suchstring=&query_id=&sprache=D&fund_typ=TAB&methode=&vt=&verwandte=1¶ge_ret=0&seite=1&p_lfd_nr=20&p_news=&p_sprachkz=D&p_uid=gasts&p_aid=93524339&hlp_nr=2&p_janein=J. Gesehen 22.11.2009Google Scholar
  11. Grundy SM, Cleeman JI, Merz CNB et al. (2004) Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 110:227–239PubMedCrossRefGoogle Scholar
  12. Krumholz HM, Radford MJ, Ellerbeck EF et al. (1995) Aspirin in the treatment of acute myocardial infarction in elderly Medicare beneficiaries. Patterns of use and outcomes. Circulation 92(10):2841–2847PubMedGoogle Scholar
  13. Kyriakides ZS, Kourouklis S, Kontaras K (2007) Acute coronary syndromes in the elderly. Drugs Aging 24(11):901–912PubMedCrossRefGoogle Scholar
  14. Lenderink T, Boersma E, Gitt AK et al. (2006) Patients using statin treatment within 24 h after admission for ST-elevation acute coronary syndromes had lower mortality than nonusers: a report from the first Euro Heart Survey on acute coronary syndromes. Eur Heart J 27(15):1799–1804PubMedCrossRefGoogle Scholar
  15. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7–22CrossRefGoogle Scholar
  16. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group (1994) Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 343(8893):311–322Google Scholar
  17. Petersen S, Peto V, Scarborough P, Rayner M (2005) Coronary heart disease statistics. London, British Heart FoundationGoogle Scholar
  18. Schuler J, Maier B, Behrens S, Thimme W (2006) Present treatment of acute myocardial infarction in patients over 75 years—data from the Berlin Myocardial Infarction Registry (BHIR). Clin Res Cardiol 95(7):360–367PubMedCrossRefGoogle Scholar
  19. Shepherd J, Blauw GJ, Murphy MB et al. (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360:1623–1630PubMedCrossRefGoogle Scholar
  20. Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology, Bassand JP, Hamm CW et al. (2007) Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 28(13):1598–1660PubMedCrossRefGoogle Scholar
  21. The TIME Investigators (2001) Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial. Lancet 358:951–957CrossRefGoogle Scholar

Literatur

  1. Alikhan R, Cohen AT, Combe S et al. (2003) Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis 14(4):341–346PubMedCrossRefGoogle Scholar
  2. Fuster V, Rydén LE, Cannom DS et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114(7):e257–e354Google Scholar
  3. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW (2008) Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl):381S–453SPubMedCrossRefGoogle Scholar
  4. Nieuwlaat R, Capucci A, Lip GY et al. (2006) Euro Heart Survey Investigators. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 27(24):3018–3026PubMedCrossRefGoogle Scholar
  5. Rossol-Haseroth K, Vogel CU, Reinecke F et al. (2002) Empfehlungen zur Thromboembolieprophylaxe bei internistischen Patienten im Alter. Internist (Berl) 43(9):1134–1147PubMedCrossRefGoogle Scholar
  6. Roy D, Talajic M, Nattel S et al. (2008) Atrial fibrillation and congestive heart failure investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 358(25):2667–2677PubMedCrossRefGoogle Scholar
  7. Savelieva I, Camm AJ (2001) Clinical trends in atrial fibrillation at the turn of the millenium. J Intern Med 250(5):369–372PubMedCrossRefGoogle Scholar
  8. Spyropoulos AC, Merli G (2006) Management of venous thromboembolism in the elderly. Drugs Aging 23(8):651–671PubMedCrossRefGoogle Scholar

Literatur

  1. Arzneimittelkommission der deutschen Ärzteschaft (2008) Fluoroquinolones: psychiatric adverse effects. Prescrire Int 17(93):20Google Scholar
  2. Board M, Allen SC (2006) A simple drawing test to identify patients who are unlikely to be able to learn to use an inhaler. Int J Clin Pract 60(5):510–513PubMedCrossRefGoogle Scholar
  3. Buhl R, Berdel D, Criée CP et al. (2006) Leitlinie zur Diagnostik und Therapie von Patienten mit Asthma. Pneumologie 60(3):139–177PubMedCrossRefGoogle Scholar
  4. GOLD (Global Initiative for Chronic Obstructive Lung Disease) (2007) Global strategy for the diagnosis, management and prevention of COPD. http://www.goldcopd.org.Gesehen11.8.08Google Scholar
  5. Jara M, Lanes SF, Wentworth C 3rd, May C, Kesten S (2007) Comparative safety of long-acting inhaled bronchodilators: a cohort study using the UK THIN primary care database. Drug Saf 30(12):1151–1160PubMedCrossRefGoogle Scholar
  6. Müller D, Szucs TD (2007) Influenza vaccination coverage rates in 5 European countries: a population-based cross-sectional analysis of the seasons 02/03, 03/04 and 04/05. Infection 35(5):308–319PubMedCrossRefGoogle Scholar
  7. Mathers CD, Loncar D (2006) Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3(11):e442PubMedCrossRefGoogle Scholar
  8. Rabe KF, Hurd S, Anzueto A et al. (2007) Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176(6):532–555PubMedCrossRefGoogle Scholar
  9. Salpeter SR (2007) Bronchodilators in COPD: impact of beta-agonists and anticholinergics on severe exacerbations and mortality. Int J Chron Obstruct Pulmon Dis 2(1):11–18PubMedGoogle Scholar
  10. Schirnhofer L, Lamprecht B, Vollmer WM, Allison MJ, Studnicka M, Jensen RL, Buist AS (2007) COPD prevalence in Salzburg, Austria: results from the Burden of Obstructive Lung Disease (BOLD) Study. Chest 131(1):29–36PubMedCrossRefGoogle Scholar
  11. Weel C van (1996) Chronic diseases in general practice: the longitudinal dimension. Eur J Gen Pract 2:17–21CrossRefGoogle Scholar

Literatur

  1. Chrischilles EA, Butler CD, Davis CS, Wallace RB (1991) A model of lifetime osteoporosis impact. Arch Intern Med 151:2026–2032PubMedCrossRefGoogle Scholar
  2. Dachverband Osteologie (2009) DVO-Leitlinie 2009 zur Prophylaxe, Diagnostik und Therapie der Osteoporose bei Erwachsenen, Langfassung: http://www.dv-osteologie.org/uploads/leitlinien/DVO-Leitlinie%202009%20Langfassung%2015.10.2009.pdf, Kurzfassung: http://www.dv-osteologie.org/uploads/leitlinien/DVO-Leitlinie%202009%20Kurzfassung%2015.10.09_1.pdf. Gesehen 7.12.2009Google Scholar
  3. Dachverband der Deutschsprachigen Osteologischen Fachgesellschaften (2006) Kitteltaschenfassung 2006 der Leitlinie des Dachverbands der Deutschsprachigen Osteologischen Fachgesellschaften zur Prophylaxe, Diagnostik und Therapie der Osteoporose bei Frauen ab der Menopause, bei Männern ab dem 60. Lebensjahr. http://www.dv-osteologie.org/uploads/leitlinien/Kitteltasche_DVO-Leitlinien_15-03-06.pdf. Gesehen 7.12.09Google Scholar
  4. Duque G, Mallet L, Roberts A, Gingrass S, Kremer R, Sainte-Marie LG, Kiel DP (2007) To treat or not to treat, that is the question: proceedings of the Quebec symposium for the treatment of osteoporosis in long-term care institutions,.Saint-Hyacinthe, Quebec, November 5th, 2004. J Am Med Dir Assoc 8(3 Suppl 2):e67–e73PubMedCrossRefGoogle Scholar
  5. Looker AC, Orwoll ES, Johnston CC Jr et al. (1997) Prevalence of low femoral bone density in older US adults from NHANES III. J Bone Miner Res 12:1761–1768PubMedCrossRefGoogle Scholar
  6. Lyles KW, Colón-Emeric CS, Magaziner JS et al. (2007) HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357(18):1799–1809PubMedCrossRefGoogle Scholar

Literatur

  1. Abram K, Pedersen-Bjergaard U, Borch-Johnsen K, Thorsteinsson B (2006) Frequency and risk factors of severe hypoglycemia in insulin-treated type 2 diabetes: a literature survey. J Diabetes Complications 20:402–408CrossRefGoogle Scholar
  2. ACCORD (The Action to Control Cardiovascular Risk in Diabetes Study Group) (2008) Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358:2545–2559CrossRefGoogle Scholar
  3. ADVANCE (The ADVANCE Collaborative Group) (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572CrossRefGoogle Scholar
  4. Allen KV, Frier BM, Strachan MWJ (2004) The relationship between type 2 diabetes and cognitive dysfunction: longitudinal studies and their methodological limitations. Eur J Pharmacol 490:169–175PubMedCrossRefGoogle Scholar
  5. American Diabetes Association (2009) Standards of medical care in diabetes. Diabetes Care, 32:S13–S61CrossRefGoogle Scholar
  6. Braun A, Muller UA, Leppert K, Schiel R (2004) Structured treatment and teaching of patients with type 2 diabetes mellitus and impaired cognitive function — the DICOF trial. Diabet Med 21:999–1006PubMedCrossRefGoogle Scholar
  7. Burkhardt H, Karaminejad E, Gladisch R (2006) A short performance-test can help to predict adherence to self-administration of insulin in elderly patients with diabetes. Age Ageing 35:449–452PubMedCrossRefGoogle Scholar
  8. Cryer PE, Davis SN, Shamon H (2003) Hypoglycemia in Diabetes. Diabetes Care 26:1902–1912PubMedCrossRefGoogle Scholar
  9. Dargie HJ, Hildebrandt PR, Riegger GA et al. (2007) A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. J Am Coll Cardiol 49(16):1696–1704PubMedCrossRefGoogle Scholar
  10. DCCT (The Diabetes Control and Complications Trial Research Group) (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRefGoogle Scholar
  11. DDG (Deutsche Diabetesgesellschaft) (2009) Diabetes im Alter. http://www.deutsche-diabetes-gesellschaft.de/redaktion/mitteilungen/leitlinien/Uebersicht_Praxisleitlinien.php. Gesehen 15.12.2009Google Scholar
  12. Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696–1705PubMedCrossRefGoogle Scholar
  13. Duckworth W, Abraira C, Moritz T et al. (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360(2):129–139PubMedCrossRefGoogle Scholar
  14. Erdmann E, Charbonnel B, Wilcox RG et al. (2007) Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease. Diabetes Care 30:2773–2778PubMedCrossRefGoogle Scholar
  15. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383–393PubMedCrossRefGoogle Scholar
  16. Hader C et al. (2005) Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Alter. Diabet Stoffw 13:31–56Google Scholar
  17. Hauner H (2006) Die Kosten des Diabetes und seiner Komplikationen in Deutschland. Dtsch Med Wochenschr 131:S240–S242PubMedCrossRefGoogle Scholar
  18. Holstein A, Plaschke A, Egberts EH (2001) Lower incidence of severe hypoglycemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 17:467–473PubMedCrossRefGoogle Scholar
  19. Josephkutty S, Potter JM (1990) Comparison of tolbutamide and metformin in elderly diabetic patients. Diabet Med 7:510–514PubMedCrossRefGoogle Scholar
  20. Lipscombe LL, Gomes T, Lèvesque LE, Hux JE, Juurlink DN, Alter DA (2007) Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 298:2634–2653PubMedCrossRefGoogle Scholar
  21. Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR (2008) Use of thiazolidinediones and fracture risk. Arch Intern Med 168:820–825PubMedCrossRefGoogle Scholar
  22. Meneilly GS (1999) Pathophysiology of type 2 diabetes in the elderly. Clin Geriatr Med 15:239–253PubMedGoogle Scholar
  23. Mooradian AD, Albert SG, Wittry S, Chehade J, Kim J, Bellrichard B (2000) Dose response profile of acrabose in older subjects with type 2 diabetes. Am J Med Sci 319:334–337PubMedCrossRefGoogle Scholar
  24. Moty C, Barberger-Gateau P, De Sarasqueta AM, Teare GF, Henrad JC (2003) Risk adjustment of quality indicators in french long term care facilities for elderly people. A preliminary study. Rev Epidemiol Sante Publique 51:327–338PubMedGoogle Scholar
  25. National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1–S246. http://www.kidney.org/professionals/KDOQI. Gesehen 15.1.2009CrossRefGoogle Scholar
  26. Phillips P, Phil D, Rolls B et al. (1984) Reduced thirst after water dehydration in healthy elderly men. N Engl J Med 311:753–759PubMedCrossRefGoogle Scholar
  27. Pickering G (2004) Frail elderly, nutritional status and drugs. Arch Gerontol Geriatr 38:174–180PubMedCrossRefGoogle Scholar
  28. Schwarz SL, Gerich JE, Marcellari A, Jean-Louis L, Purkayastha D, Baron MA (2008) Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naive elderly patients with type 2 diabetes. Diab Obes Metab 10:652–660CrossRefGoogle Scholar
  29. Shepherd J, Blauw GJ, Murphy MB et al. (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360:1623–1630PubMedCrossRefGoogle Scholar
  30. Shorr RI, Ray WA, Daugherty JR, Griffin MR (1997) Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med 157:1681–1686PubMedCrossRefGoogle Scholar
  31. Staa T van, Abenhaim L, Monette J (1997) Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 50(6):735–741PubMedCrossRefGoogle Scholar
  32. Skyler JS, Bergenstal R, Bonow RO et al. (2009) Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 20;53(3):298–304CrossRefGoogle Scholar
  33. The Diabetes Prevention Program Research Group (Prepared by Jill Crandall, David Schade, Yong Ma et al.) (2006) The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. J Gerontol Med Sci 2006, 61A: 1075–1081Google Scholar
  34. Thomson FJ, Masson EA, Leeming JT, Boulton AJ (1991) Lack of knowledge of symproms of hypoglycaemia by elderly diabetic patients. Age Ageing 20:404–406PubMedCrossRefGoogle Scholar
  35. Thorslund S, Toss G, Nilsson I, Schenk H von, Symbwerg T, Zetterqvist H (1990) Prevalence of protein-energy malnutrition in a large population of elderly people at home. Scand J Prim Health Care 8:243–248PubMedCrossRefGoogle Scholar
  36. Turnbull PJ, Sinclair AJ (2002) Evaluation of nutritional status and its relationship with functional status in older citizens with diabetes mellitus using the Mini Nutritional Assessment (MNA) tool. A preliminary investigation. J Nutr Health Aging 6:116–120Google Scholar
  37. UKPDS (UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 1998, 352:854–865CrossRefGoogle Scholar
  38. Van Den Berghe G, Wouters P, Weekers F et al. (2001) Intensive insulin therapy in critically ill patients. N Engl J Med 345:1359–1367PubMedCrossRefGoogle Scholar
  39. Staa T van, Abenhaim L, Monette J (1997) Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 50(6):735–741PubMedCrossRefGoogle Scholar
  40. Wehling M (2008) Arzneimitteltherapie im Alter: Zu viel und zu wenig, was tun? Ein neues Bewertungssystem: fit for the aged (FORTA). Dtsch Med Wochenschr 133:2289–2291PubMedCrossRefGoogle Scholar
  41. Yki-Järvinen H, Kauppila M, Kujansuu E et al. (1992) Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 327:1426–1433PubMedCrossRefGoogle Scholar
  42. Zeyfang A, Feucht I, Fetzer G, Bausenhardt C, Ahl V (2001) Eine strukturierte geriatrische Diabetiker-Schulung (SGS) ist sinnvoll. Diabet Stoffw 10:203–207Google Scholar

Literatur

  1. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P (2003) Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 60:387–392PubMedCrossRefGoogle Scholar
  2. Aarsland D, Ballard C, Walker Z et al. (2009) Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 8:613–618PubMedCrossRefGoogle Scholar
  3. Adler G, Teufel M, Drach LM (2003) Pharmacological treatment of frontotemporal dementia: treatment response to the MAO-A inhibitor moclobemide. Int J Geriatr Psychiatry 18:653–655PubMedCrossRefGoogle Scholar
  4. Andersen-Ranberg K, Vasegaard L, Jeune B (2001) Dementia is not inevitable: a population-based study of Danish centenarians. J Gerontol B Psychol Sci Soc Sci 56:152–159Google Scholar
  5. A.T.I. Arzneimittelinformation Berlin (2005) Übersterblichkeit unter Alzheimermittel Galantamin (Reminyl). Arznei-Telegramm 36:24Google Scholar
  6. Atri A, Shaughnessy LW, Locascio JJ, Growdon JH (2008) Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 22:209–221PubMedCrossRefGoogle Scholar
  7. Ballard C, Hanney ML, Theodoulou M et al. (2009) The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 8:151–157PubMedCrossRefGoogle Scholar
  8. Benesch G, Frölich L, Riepe MW (2005) Therapie degenerativer Demenzen. In: HC Diener, N Putzki, P Berlit (Hrsg) Leitlinien für Diagnostik und Therapie in der Neurologie. 3. Aufl. Thieme, StuttgartGoogle Scholar
  9. Bowler JV (2005) Vascular cognitive impairment. J Neurol Neurosurg Psychiatry 76(Suppl 5):v35–44PubMedCrossRefGoogle Scholar
  10. Boyle PA, Malloy PF (2004) Treating apathy in Alzheimer’s disease. Dement Geriatr Cogn Disord 17:91–99PubMedCrossRefGoogle Scholar
  11. Buscemi N, Vandermeer B, Hooton N et al. (2006) Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. BMJ 332:385–393PubMedCrossRefGoogle Scholar
  12. Camicioli R, Fisher N (2004) Progress in clinical neurosciences: Parkinson’s disease with dementia and dementia with Lewy bodies. Can J Neurol Sci 31:7–21PubMedGoogle Scholar
  13. Cardinali DP, Brusco LI, Liberczuk C, Furio AM (2002) The use of melatonin in Alzheimer’s disease. Neuro Endocrinol Lett 23(Suppl 1):20–23PubMedGoogle Scholar
  14. Craig D, Birks J (2005) Rivastigmine for vascular cognitive impairment. Cochrane Database Syst Rev CD004744Google Scholar
  15. Craig D, Birks J (2006) Galantamine for vascular cognitive impairment. Cochrane Database Syst Rev CD004746Google Scholar
  16. DGPPN (Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde), DGN (Deutsche Gesellschaft für Neurologie) (2009) S3-Leitlinie Demenzen. www.dgn.org.Gesehen 11.01.2010Google Scholar
  17. Diener HC, Putzki N (Hrsg) (2008) Leitlinien für Diagnostik und Therapie in der Neurologie. Diagnostik degenerativer Demenzen. Thieme, Stuttgart, S 154–167Google Scholar
  18. European Medicines Agency (2009) Committee for medicinal products for human use. Guidelines on medicinal products for the treatment of Alzheimer’s disease and other dementias. http://www.ema.europa.eu/pdfs/human/ewp/0055395en.pdf. Available 11.01.2010Google Scholar
  19. Emre M, Aarsland D, Albanese A et al. (2004) Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 351:2509–2518PubMedCrossRefGoogle Scholar
  20. Ferri CP, Prince M, Brayne C et al. (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366:2112–2117PubMedCrossRefGoogle Scholar
  21. Fuchs GA, Gemende I, Herting B et al. (2004) Dementia in idiopathic Parkinson’s syndrome. J Neurol 251(Suppl 6):VI/28–32Google Scholar
  22. Hallauer JF, Schons M, Smala A, Berger K (2000) Untersuchungen von Krankheitskosten bei Patienten mit Alzheimer-Erkrankung in Deutschland. Gesundheitsökon Qualitätsmanag 5:73–79Google Scholar
  23. Hansen RA, Gartlehner G, Webb AP et al. (2008) Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. Clin Interv Aging 3:211–225PubMedGoogle Scholar
  24. Herrmann N, Lanctot KL (2005) Do atypical antipsychotics cause stroke? CNS Drugs 19:91–103PubMedCrossRefGoogle Scholar
  25. Hogan DB (2006) Donepezil for severe Alzheimer’s disease. Lancet 367:1031–1032PubMedCrossRefGoogle Scholar
  26. Hogan DB, Patterson C (2002) Progress in clinical neurosciences: Treatment of Alzheimer’s disease and other dementias — review and comparison of the cholinesterase inhibitors. Can J Neurol Sci 29:306–314PubMedGoogle Scholar
  27. Hogan DB, Goldlist B, Naglie G, Patterson C (2004) Comparison studies of cholinesterase inhibitors for Alzheimer’s disease. Lancet Neurol 3:622–626PubMedCrossRefGoogle Scholar
  28. Ibach B, Lange K, Haen E (2003) Das cholinerge System und die Therapie der Alzheimer-Demenz. In: Förstl H (Hrsg) Antidementiva. Urban & Fischer, München, S 93–143Google Scholar
  29. IQWIG (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen) (2009) Memantin bei Alzheimer Demenz. www.iqwig.de/index.404.html. Gesehen 11.01.2010Google Scholar
  30. Kavirajan H, Schneider LS (2007) Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol 6:782–792PubMedCrossRefGoogle Scholar
  31. Lobo A, Launer LJ, Fratiglioni L et al. (2000) Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54:S4–S9PubMedGoogle Scholar
  32. Lopez OL, Becker JT, Wahed AS et al. (2009) Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 80:600–607PubMedCrossRefGoogle Scholar
  33. Maidment I, Fox C, Boustani M (2006) Cholinesterase inhibitors for Parkinson’s disease dementia. Cochrane Database Syst Rev, CD004747Google Scholar
  34. McKeith IG, Dickson DW, Lowe J et al. (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65:1863–1872PubMedCrossRefGoogle Scholar
  35. Müller U, Wolf H, Kiefer M, Gertz HJ (2003) Ein systematischer Vergleich nationaler und internationaler Demenzrichtlinien. Fortschr Neurol Psychiatr 71:285–295PubMedCrossRefGoogle Scholar
  36. Neary D, Snowden J, Mann D (2005) Frontotemporal dementia. Lancet Neurol 2005;4:771–780PubMedCrossRefGoogle Scholar
  37. Ott A, Breteler MM, Harskamp F van, Stijnen T, Hofman A (1998) Incidence and risk of dementia. The Rotterdam Study. Am J Epidemiol 147:574–580PubMedGoogle Scholar
  38. Samuel W, Caligiuri M, Galasko D et al. (2000) Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry 15:794–802PubMedCrossRefGoogle Scholar
  39. Schneider LS, Dagerman K, Insel PS (2006) Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 14:191–210PubMedCrossRefGoogle Scholar
  40. Snitz BE, O’Meara ES, Carlson MC et al.(2009) Ginkgo Evaluation of Memory (GEM) Study Investigators. Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA 302:2663–2670PubMedCrossRefGoogle Scholar
  41. Statistisches Bundesamt (2009) Bevölkerung Deutschlands bis 2060 — Ergebnisse der 12. koordinierten Bevölkerungsvorausberechnung, www.destatis.de. Gesehen 11.01.2010Google Scholar
  42. Winblad B, Kilander L, Eriksson S et al. (2006) Donepezil in patients with severe Alzheimer’s disease: double-blind, parallel-group, placebo-controlled study. Lancet 367:1057–1065PubMedCrossRefGoogle Scholar

Literatur

  1. Aarsland D, Zaccai J, Brayne C (2005) A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord 20(10):1255–1263PubMedCrossRefGoogle Scholar
  2. Bennett DA, Beckett LA, Murray AM, Shannon KM, Goetz CG, Pilgrim DM, Evans DA (1996) Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 334(2):71–76PubMedCrossRefGoogle Scholar
  3. Brooks DJ (2004) Safety and tolerability of COMT inhibitors. Neurology 62(Suppl 1):S39–S46PubMedGoogle Scholar
  4. Buhmann C (2008) Diagnostik und Therapie des Morbus Parkinson beim alteren Patienten. NeuroGeriatrie 5:137–145Google Scholar
  5. Chou KL, Messing S, Oakes D, Feldman PD, Breier A, Friedman JH (2005) Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments. Clin Neuropharmacol 28(5):215–219PubMedCrossRefGoogle Scholar
  6. Csoti I, Fornadi F (2008) Medikamentöse Interaktionen in der Parkinson-Therapie. NeuroGeriatrie 5:160–168Google Scholar
  7. Dell’Agnello G, Ceravolo R, Nuti A et al. (2001) SSSRIs do not worsen Parkinson’s disease: evidence from an open-label, prospective study. Clin Neuropharmacol 24(4):221–227PubMedCrossRefGoogle Scholar
  8. Deutsche Gesellschaft fur Neurologie (2009) Leitlinien der Deutschen Gesellschaft fur Neurologie 2008. Parkinson-Syndrome. Diagnostik und Therapie. http://www.dgn.org.Gesehen 18.12.2009Google Scholar
  9. Ebersbach G (2008) Depressive Störungen bei der Parkinson-Erkrankung. NeuroGeriatrie 5:146–153Google Scholar
  10. Emre M, Aarsland D, Albanese A et al. (2004) Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 351(24):2509–2518PubMedCrossRefGoogle Scholar
  11. Fahn S, Oakes D, Shoulson I et al. (2004) Levodopa and the progression of Parkinson’s disease. N Engl J Med 351(24):2498–2508PubMedCrossRefGoogle Scholar
  12. Goetz CG, Blasucci LM, Leurgans S, Pappert EJ (2000) Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 55(6):789–794PubMedGoogle Scholar
  13. Holroyd S, Currie L, Wooten GF (2001) Prospective study of hallucinations and delusions in Parkinson’s disease. J Neurol Neurosurg Psychiatry 70(6):734–738PubMedCrossRefGoogle Scholar
  14. Janno S, Holi M, Tuisku K, Wahlbeck K (2004) Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia in patients. Am J Psychiatry 161(1):160–163PubMedCrossRefGoogle Scholar
  15. Jenner P (2005) A novel dopamine agonist for the transdermal treatment of Parkinson’s disease. Neurology 65(2 Suppl 1): S3–S5PubMedGoogle Scholar
  16. Mitchell SL, Sullivan EA, Lipsitz LA (1997) Exclusion of elderly subjects from clinical trials for Parkinson disease. Arch Neurol 54(11):1393–1398PubMedGoogle Scholar
  17. Nutt JG (2003) Long-term L-DOPA therapy: challenges to our understanding and for the care of people with Parkinson’s disease. Exp Neurol 184(1):9–13PubMedCrossRefGoogle Scholar
  18. Parkinson Study Group (2000) A randomized controlled trial comparing pramipexole with levodopa in early Parkinson’s disease: design and methods of the CALM-PD Study. Clin Neuropharmacol 23(1):34–44CrossRefGoogle Scholar
  19. Poewe WH, Wenning GK (1998) The natural history of Parkinson’s disease. Ann Neurol 44(3 Suppl 1):S1–S9PubMedGoogle Scholar
  20. Pollak P, Tison F, Rascol O et al. (2004) Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 75(5):689–695PubMedCrossRefGoogle Scholar
  21. Rajput AH, Offord KP, Beard CM, Kurland LT (1984) Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol 16(3):278–282PubMedCrossRefGoogle Scholar
  22. Rascol O, Brooks DJ, Melamed E et al. (2005) Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in adjunct therapy with rasagiline given once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365(9463): 947–954PubMedCrossRefGoogle Scholar
  23. Reddy S, Factor SA, Molho ES, Feustel PJ (2002) The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord 17(4):676–681PubMedCrossRefGoogle Scholar
  24. Rijk MC de, Launer LJ, Berger K (2000) Prevalence of Parkinson’s disease in Europe: A collaborative study of populationbased cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54(11 Suppl 5):S21–S23Google Scholar
  25. Santamaria J, Tolosa E, Valles A (1986) Parkinson’s disease with depression: a possible subgroup of idiopathic parkinsonism. Neurology 36(8):1130–1133PubMedGoogle Scholar
  26. Schwarz J, Storch A (2007) Parkinson-Syndrome. Kohlhammer, StuttgartGoogle Scholar
  27. Starkstein SE, Preziosi TJ, Bolduc PL, Robinson RG (1990) Depression in Parkinson’s disease. J Nerv Ment Dis 178(1):27–31PubMedCrossRefGoogle Scholar
  28. Stephen PJ, Williamson J (1984) Drug-induced parkinsonism in the elderly. Lancet 2(8411):1082–1083PubMedCrossRefGoogle Scholar
  29. Szegedi A, Jansen WT, Willigenburg AP van, van der Meulen E, Stassen HH, Thase ME (2009) Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry 70:344–353PubMedCrossRefGoogle Scholar
  30. The Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 328(3):176–183CrossRefGoogle Scholar
  31. Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN (1998) Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Neurology 50(5):1323–1326PubMedGoogle Scholar

Literatur

  1. Alexopoulos GS (2005) Depression in the elderly. Lancet 365:1961–1970PubMedCrossRefGoogle Scholar
  2. Alexopoulos GS, Katz IR, Reynolds CF 3rd, Carpenter D, Docherty JP (2001) The expert consensus guideline series. Pharmacotherapy of depressive disorders in older patients. Postgrad Med Spec No Pharmacotherapy:1–86Google Scholar
  3. Alexopoulos GS, Borson S, Cuthbert BN, Devanand DP, Mulsant BH, Olin JT, Oslin DW (2002) Assessment of late life depression. Biol Psychiatry 52:164–174PubMedCrossRefGoogle Scholar
  4. Bauer M, Bschor T, Pfennig A, Whybrow PC, Angst J, Versiani M, Moller HJ (2007) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World J Biol Psychiatry 8:67–104PubMedCrossRefGoogle Scholar
  5. Bondareff W, Alpert M, Friedhoff AJ, Richter EM, Clary CM, Batzar E (2000) Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life. Am J Psychiatry 157:729–736PubMedCrossRefGoogle Scholar
  6. Cipriani A, Furukawa TA, Salanti G et al. (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373:746–758PubMedCrossRefGoogle Scholar
  7. DGPPN, BAK, KBV et al. (Hrsg) (2009) S3-Leitlinie/Nationale Versorgungsleitlinie Unipolare Depression. 1. Aufl, DGPPN, AZQ, AWMF — Berlin, Dusseldorf. http://media.dgppn.de/mediadb/media/dgppn/pdf/leitlinien/s3-nvl-unipolaredepression-lf.pdf. Gesehen 11.01.2010Google Scholar
  8. Hawton K, Heeringen K van (2009) Suicide. Lancet 373:1372–1381PubMedCrossRefGoogle Scholar
  9. Heok KE, Ho R (2008) The many faces of geriatric depression. Curr Opin Psychiatry 21:540–545PubMedCrossRefGoogle Scholar
  10. Pinquart M, Duberstein PR, Lyness JM (2006) Treatments for later-life depressive conditions: a meta-analytic comparison of pharmacotherapy and psychotherapy. Am J Psychiatry 163:1493–1501PubMedCrossRefGoogle Scholar
  11. Pinquart M, Duberstein PR, Lyness JM (2007) Effects of psychotherapy and other behavioral interventions on clinically depressed older adults: a meta-analysis. Aging Ment Health 11:645–657PubMedCrossRefGoogle Scholar
  12. Raskin J, Wiltse CG, Siegal A et al. (2007) Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 164:900–909PubMedCrossRefGoogle Scholar
  13. Tess AV, Smetana GW (2009) Medical evaluation of patients undergoing electroconvulsive therapy. N Engl J Med 360:1437–1444PubMedCrossRefGoogle Scholar

Literatur

  1. Ancoli-Israel S, Cooke JR (2005) Prevalence and comorbidity of insomnia and effect on functioning in elderly populations. J Am Geriatr Soc 53:S264–S271PubMedCrossRefGoogle Scholar
  2. Bloom HG, Ahmed I, Alessi CA et al. (2009) Evidence-based recommendations for the assessment and management of sleep disorders in older persons. J Am Geriatr Soc 57:761–789PubMedCrossRefGoogle Scholar
  3. Culberson JW, Ziska M (2008) Prescription drug misuse/abuse in the elderly. Geriatrics 63:22–31PubMedGoogle Scholar
  4. Dolder C, Nelson M, McKinsey J (2007) Use of non-benzodiazepine hypnotics in the elderly: are all agents the same? CNS Drugs 21:389–405PubMedCrossRefGoogle Scholar
  5. Dundar Y, Dodd S, Strobl J et al. (2004) Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. Hum Psychopharmacol 19:305–322PubMedCrossRefGoogle Scholar
  6. Erman MK (2005) Therapeutic options in the treatment of insomnia. J Clin Psychiatry 66(Suppl 9):18–23PubMedGoogle Scholar
  7. Flaherty JH (2008) Insomnia among hospitalized older persons. Clin Geriatr Med 24:51–67PubMedCrossRefGoogle Scholar
  8. Foley DJ, Monjan A, Simonsick EM et al. (1999) Incidence and remission of insomnia among elderly adults: an epidemiologic study of 6,800 persons over three years. Sleep 22(Suppl 2):S366–S372PubMedGoogle Scholar
  9. Glass J, Lanctot KL, Herrmann N et al. (2005) Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ 331:1169PubMedCrossRefGoogle Scholar
  10. Kupfer DJ, Reynolds CF 3rd (1997) Management of insomnia. N Engl J Med 336:341–346PubMedCrossRefGoogle Scholar
  11. Melton ST, Wood JM, Kirkwood CK (2005) Eszopiclone for insomnia. Ann Pharmacother 39:1659–1666PubMedCrossRefGoogle Scholar
  12. Svarstad BL, Mount JK (2001) Chronic benzodiazepine use in nursing homes: effects of federal guidelines, resident mix, and nurse staffing. J Am Geriatr Soc 49:1673–1678PubMedCrossRefGoogle Scholar
  13. Vaz Fragoso CA, Gill TM (2007) Sleep complaints in community-living older persons: a multifactorial geriatric syndrome. J Am Geriatr Soc 55:1853–1866PubMedCrossRefGoogle Scholar
  14. Wolkove N, Elkholy O, Baltzan M et al. (2007) Sleep and aging: 1. Sleep disorders commonly found in older people. CMAJ 176:1299–1304PubMedGoogle Scholar

Literatur

  1. Ammon HPT (Hrsg) (2001) Arzneimittelneben-und wechselwirkungen. Wissenschaftliche Verlagsgesellschaft, StuttgartGoogle Scholar
  2. Andrade SE, Martinez C, Walker AM (1998) Comparative safety evaluation of non-narcotic analgesics. J Clin Epidemiol 51(12):1357–1365PubMedCrossRefGoogle Scholar
  3. Arzneimittelkommission der deutschen Arzteschaft (2004) Arzneimittelbrief 2003, 37, 6b., Deutsches Arzteblatt 101:A3365Google Scholar
  4. Attal N, Cruccu G, Haanpää M et al. (2006) EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 13(11):1153–1169PubMedCrossRefGoogle Scholar
  5. Baxter H (Ed) (2008) Stockley’s drug interactions 2008. Pharmaceutical Press, LondonGoogle Scholar
  6. Bombardier C, Laine L, Reicin A et al. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343(21):1520–1528PubMedCrossRefGoogle Scholar
  7. Bradley JD, Brandt KD, Katz BP, Kalasinski LA, Ryan SI (1991) Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med 325(2):87–91PubMedCrossRefGoogle Scholar
  8. Brattberg G, Parker MG, Thorslund M (1996) The prevalence of pain among the oldest old in Sweden. Pain 67(1):29–34PubMedCrossRefGoogle Scholar
  9. Brodie MJ, Overstall PW, Giorgi L (1999) Multicentre, doubleblind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res 7(1):81–87CrossRefGoogle Scholar
  10. Bruckenthal P (2008) Assessment of pain in the elderly adult. Clin Geriatr Med 24(2):213–236PubMedCrossRefGoogle Scholar
  11. Chan FK, Hung LC, Suen BY et al. (2002) Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347(26):2104–2110PubMedCrossRefGoogle Scholar
  12. Charette SL, Ferrell BA (2007) Rheumatic diseases in the elderly: assessing chronic pain. Rheum Dis Clin North Am 33(1):109–122PubMedCrossRefGoogle Scholar
  13. Cohen HW, Gibson G, Alderman MH (2000) Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med 108(1):2–8PubMedCrossRefGoogle Scholar
  14. Cruccu G, Anand P, Attal N et al. (2004) EFNS guidelines on neuropathic pain assessment. Eur J Neurol 11(3):153–162PubMedCrossRefGoogle Scholar
  15. Dworkin RH, Backonja M, Rowbotham MC et al. (2003) Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol 60(11):1524–1534PubMedCrossRefGoogle Scholar
  16. Ferrell BA, Ferrell BR, Osterweil D (1990) Pain in the nursing home. J Am Geriatr Soc 38(4):409–414PubMedGoogle Scholar
  17. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH (2005) Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 118(3):289–305PubMedCrossRefGoogle Scholar
  18. Frondini C, Lanfranchi G, Minardi M, Cucinotta D (2007) Affective, behavior and cognitive disorders in the elderly with chronic musculoskelatal pain: the impact on an aging population. Arch Gerontol Geriatr 44(Suppl 1):167–171PubMedCrossRefGoogle Scholar
  19. Gaudreau JD, Gagnon P, Roy MA, Harel F, Tremblay A (2007) Opioid medications and longitudinal risk of delirium in hospitalized cancer patients. Cancer 109(11):2365–2373PubMedCrossRefGoogle Scholar
  20. Giron MS, Fastbom J, Winblad B (2005) Clinical trials of potential antidepressants: to what extent are the elderly represented: a review. Int J Geriatr Psychiatry 20(3):201–217PubMedCrossRefGoogle Scholar
  21. Haslam C, Nurmikko T (2008) Pharmacological treatment of neuropathic pain in older persons. Clin Interv Aging (1):111–120Google Scholar
  22. Hedenmalm K, Spigset O (2002) Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole). Eur J Clin Pharmacol 58:265–274PubMedCrossRefGoogle Scholar
  23. Henry D, Lim LL, Garcia Rodriguez LA et al. (1996) Variability in risk of gastrointestinal complications with individual nonsteroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 312(7046):1563–1566PubMedGoogle Scholar
  24. Hippisley-Cox J, Coupland C, Logan R (2005) Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 331(7528):1310–1316PubMedCrossRefGoogle Scholar
  25. Jüni P, Rutjes AW, Dieppe PA (2202) Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ 324(7349):1287–1288CrossRefGoogle Scholar
  26. Kean WF, Rainsford KD, Kean IR (2008) Management of chronic musculoskeletal pain in the elderly: opinions on oral medication use. Inflammopharmacology 6(2):53–75CrossRefGoogle Scholar
  27. Lapane KL, Spooner JJ, Mucha L, Straus WL (2001) Effect of nonsteroidal anti-inflammatory drug use on the rate of gastrointestinal hospitalizations among people living in long-term care. J Am Geriatr Soc 49(5):577–584PubMedCrossRefGoogle Scholar
  28. Laurell H, Hansson LE, Gunnarsson U (2006) Acute abdominal pain among elderly patients. Gerontology 52:339–344PubMedCrossRefGoogle Scholar
  29. Leppik IE, Epilepsy Foundation of America (2005) Choosing an antiepileptic. Selecting drugs for older patients with epilepsy. Geriatrics 60(11):42–47PubMedGoogle Scholar
  30. Mattenklodt P, Ingenhorst A, Wille C et al. (2008) Multimodale Gruppentherapie bei Senioren mit chronischen Schmerzen. Schmerz 22:551–5561PubMedCrossRefGoogle Scholar
  31. McCleane G (2008) Pain perception in the elderly patient. Clin Geriatr Med 24(2):203–211PubMedCrossRefGoogle Scholar
  32. McGettigan P, Henry D (2006) Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296(13):1633–1644PubMedCrossRefGoogle Scholar
  33. McQuay HJ (1997) Opioid use in chronic pain. Acta Anaesthesiol Scand 41(1 Pt 2):175–183PubMedCrossRefGoogle Scholar
  34. Mercadante S, Arcuri E (2007) Pharmacological management of cancer pain in the elderly. Drugs Aging 24(9):761–776PubMedCrossRefGoogle Scholar
  35. Mukherjee D, Nissen SE, Topol EJ (2001) Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286(8):954–959PubMedCrossRefGoogle Scholar
  36. Namaka M, Gramlich CR, Ruhlen D, Melanson M, Sutton I, Major J (2004) A treatment algorithm for neuropathic pain. Clin Ther. 2004 Jul;26(7):951–979. Review. Erratum in: Clin Ther. 2004 Dec;26(12):2163PubMedCrossRefGoogle Scholar
  37. Nikolaus T, Zeyfang A (2004) Pharmacological treatment for persisitent non-malignant pain in older persons. Drugs Aging 21:19–41PubMedCrossRefGoogle Scholar
  38. Pergolizzi J, Boger RH, Budd K et al. (2008) Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 8(4):287–313PubMedCrossRefGoogle Scholar
  39. Ruoff GE (2002) Challenges of managing chronic pain in the elderly. Semin Arthritis Rheum 32(3 Suppl 1):43–50PubMedCrossRefGoogle Scholar
  40. Sauaia A, Min SJ, Leber C, Erbacher K, Abrams F, Fink R (2005) Postoperative pain management in elderly patients: correlation between adherence to treatment guidelines and patient satisfaction. J Am Geriatr Soc 53(2):274–282PubMedCrossRefGoogle Scholar
  41. Schmedtje JF Jr, Ji YS, Liu WL, DuBois RN, Runge MS (1997) Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J Biol Chem 272(1):601–608PubMedCrossRefGoogle Scholar
  42. Schuler MS, Basler HD, Hesselbarth S, Kaluza G, Sohn W, Nikolaus T (2004) Einfluss von Schmerzwahrnehmung, Morbiditat und aktueller Stimmung auf funktionelle Beeintrachtigung Alterer mit chronischen Schmerzen. Z Gerontol Geriatr 37(4):257–264PubMedCrossRefGoogle Scholar
  43. Semla TP, Beizer JL, Higbee MD (2003) Geriatric dosage handbook. 9th edn, Lexi Comp, HudsonGoogle Scholar
  44. Tasmuth T, Hartel B, Kalso E (2002) Venlafaxine in neuropathic pain following treatment of breast cancer. Eur J Pain 6(1):17–24PubMedCrossRefGoogle Scholar
  45. Vadalouca A, Siafaka I, Argyra E, Vrachnou E, Moka E (2006) Therapeutic management of chronic neuropathic pain: an examination of pharmacologic treatment. Ann N Y Acad Sci 1088:164–186PubMedCrossRefGoogle Scholar
  46. Van den Bemt PM, Geven LM, Kuitert NA, Risselada A, Brouwers JR (2002) The potential interaction between oral anticoagulants and acetaminophen in everyday practice. Pharm World Sci 24(5):201–204PubMedCrossRefGoogle Scholar
  47. Waldvogel HH (1996) Analgetika, Antinozizeptiva, Adjuvantien. Handbuch fur die Schmerzpraxis. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  48. Wehling, M (2008) Arzneimitteltherapie im Alter: Zu viel und zu wenig, was tun?. Dtsch Med Wochenschr 133, 2289–2291PubMedCrossRefGoogle Scholar
  49. WHO (World Health Organisation) (2007) Normative Guidelines on pain management. Geneva WHO. www.who.int/medicines/areas/quality_safety/Tagelphi_study_pain_guidelines.pdf. Gesehen 27.12.2009Google Scholar
  50. WHO (World Health Organisation) (1996) Cancer pain relief with a guide to opioid availability. 2nd edn, WHO, GenevaGoogle Scholar
  51. Won AB, Lapane KL, Vallow S, Schein J, Morris JN, Lipsitz LA (2004) Persistent nonmalignant pain and analgesic prescribing patterns in elderly nursing home residents. J Am Geriatr Soc 52(6):867–874PubMedCrossRefGoogle Scholar
  52. Yost JH, Morgan CJ (1994) Cardiovascular effects of NSAISDs. J Musculoskel Med 11:22–34Google Scholar
  53. Zwakhalen SM, Hamers JP, Abu-Saad HH, Berger MP (2006) Pain in elderly people with severe dementia: a systematic review of behavioural pain assessment tools. BMC Geriatr 6:3PubMedCrossRefGoogle Scholar

Literatur

  1. Aapro MS, Cameron DA, Pettengell R et al. (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42(15):2433–2453PubMedCrossRefGoogle Scholar
  2. Aapro MS, Link H (2008) September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 13(Suppl 3):33–36PubMedCrossRefGoogle Scholar
  3. Amado RG, Wolf M, Peeters M et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26(10):1626–1634PubMedCrossRefGoogle Scholar
  4. André T, Boni C, Mounedji-Boudiaf L et al. (2004) Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators., Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350(23):2343–2351PubMedCrossRefGoogle Scholar
  5. Ardalan B, Chua L, Tian EM et al. (1991) A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 9(4):625–630PubMedGoogle Scholar
  6. Ayanian JZ, Zaslavsky AM, Fuchs CS et al. (2003) Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol 21(7):1293–1300PubMedCrossRefGoogle Scholar
  7. Begg CB, Carbone PP (1983) Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group. Cancer 52(11):1986–1992PubMedCrossRefGoogle Scholar
  8. Boer MF de, Ryckman RM, Pruyn JF, Van den Borne HW (1997) Psychosocial correlates of cancer relapse and survival: A literature review. Patient Edu Counsel (37):215–230Google Scholar
  9. Bergh J, Holmquist M (2001) Who should not receive adjuvant chemotherapy? International databases. J Natl Cancer Inst Monogr 30:103–108PubMedGoogle Scholar
  10. Bokemeyer C, Aapro MS, Courdi A et al. (2007) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 43(2):258–270PubMedCrossRefGoogle Scholar
  11. Bonadonna G, Valagussa P (1981) Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304(1):10–15PubMedCrossRefGoogle Scholar
  12. Bonneterre J, Thürlimann B, Robertson JF et al. (2000) Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18(22):3748–3757PubMedGoogle Scholar
  13. Borkowski JM, Duerr M, Donehower RC, Rowinsky EK, Chen TL, Ettinger DS, Grochow LB (1994) Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data. Cancer Chemother Pharmacol 33(6):493–496PubMedCrossRefGoogle Scholar
  14. Bouchardy C, Rapiti E, Blagojevic S, Vlastos AT, Vlastos G (2007) Older female cancer patients: importance, causes, and consequences of undertreatment. J Clin Oncol 25(14):1858–1869PubMedCrossRefGoogle Scholar
  15. Buccheri G, Ferrigno D, Tamburini M (1996) Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 32A(7):1135–1141PubMedCrossRefGoogle Scholar
  16. Cameron D, Casey M, Press M et al. (2008) A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 112(3):533–543PubMedCrossRefGoogle Scholar
  17. Chapman JA, Meng D, Shepherd L et al. (2008) Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J Natl Cancer Inst 100(4):252–260PubMedCrossRefGoogle Scholar
  18. Christman K, Muss HB, Case LD, Stanley V (1992) Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience (see comment). JAMA 268(1):57–62PubMedCrossRefGoogle Scholar
  19. Coates AS, Keshaviah A, Thürlimann B et al. (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25(5):486–492PubMedCrossRefGoogle Scholar
  20. Cohendy R, Rubenstein LZ, Eledjam JJ (2001) The mini nutritional assessment-short form for preoperative nutritional evaluation of elderly patients. Aging (Milano 13(4):293–297Google Scholar
  21. Colleoni M, Price KN, Castiglione-Gertsch M, Gelber RD, Coates AS, Goldhirsch A (1999) Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil. International Breast Cancer Study Group. Lancet 354(9173):130–131PubMedCrossRefGoogle Scholar
  22. Corcoran ME (1997) Polypharmacy in the older patient with cancer. Cancer Control 4(5):419–428PubMedGoogle Scholar
  23. Crivellari D, Bonetti M, Castiglione-Gertsch M et al. (2000) Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol 18(7):1412–1422PubMedGoogle Scholar
  24. Crivellari D, Sun Z, Coates AS et al. (2008) Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: The BIG 1–98 Trial. J Clin Oncol 26(12):1972–1979PubMedCrossRefGoogle Scholar
  25. Cronin DP, Harlan LC, Potosky AL, Clegg LX, Stevens JL, Mooney MM (2006) Patterns of care for adjuvant therapy in a random population-based sample of patients diagnosed with colorectal cancer. Am J Gastroenterol 101(10):2308–2318PubMedCrossRefGoogle Scholar
  26. Cunningham D, Allum WH, Stenning SP et al. (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355(1):11–20PubMedCrossRefGoogle Scholar
  27. Cutsem E van, Rivera F, Berry S et al. (2009) Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 20(11):1842–1847PubMedCrossRefGoogle Scholar
  28. EBCTCG (Early Breast Cancer Trialists’ Collaborative Group) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717Google Scholar
  29. Edwards BK, Brown ML, Wingo PA et al. (2005) Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97(19):1407–1427PubMedCrossRefGoogle Scholar
  30. Edwards BK, Howe HL, Ries LA et al. (2002) Annual report to the nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. cancer burden. Cancer 94(10):2766–2792PubMedCrossRefGoogle Scholar
  31. Eichhorst B, Goede V, Hallek M (2009) Treatment of elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma 50(2):171–178PubMedCrossRefGoogle Scholar
  32. Eichhorst BF, Busch R, Stilgenbauer S et al. (2009) First line therapy with fludarabine compared to chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 114:3382–3391PubMedCrossRefGoogle Scholar
  33. Elkin EB, Hurria A, Mitra N, Schrag D, Panageas KS (2006) Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol 24(18):2757–2764PubMedCrossRefGoogle Scholar
  34. Endres HG, Wedding U, Pittrow D, Thiem U, Trampisch HJ, Diehm C (2009) Prevalence of anemia in elderly patients in primary care:impact on 5-year mortality risk and differences between men and women. Curr Med Res Opin 25(5):1143–1158PubMedCrossRefGoogle Scholar
  35. Estey, E (2007) Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 25(14):1908–1915PubMedCrossRefGoogle Scholar
  36. Ewer MS, O’Shaughnessy JA (2007) Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer. Clin Breast Cancer 7(8):600–607PubMedCrossRefGoogle Scholar
  37. Extermann M, Hurria A (2007) Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 25(14):1824–1831PubMedCrossRefGoogle Scholar
  38. Extermann M, Overcash J, Lyman GH, Parr J, Balducci L (1998) Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 16(4):1582–1587PubMedGoogle Scholar
  39. Extermann M, Meyer J, McGinnis M et al. (2004) A comprehensive geriatric intervention detects multiple problems in older breast cancer patients. Crit Rev Oncol Hematol 49(1):69–75PubMedCrossRefGoogle Scholar
  40. Facon T, Mary JY, Hulin C et al. (2007) Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06):a randomised trial. Lancet 370(9594):1209–1218PubMedCrossRefGoogle Scholar
  41. Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al. (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10(3):223–232PubMedCrossRefGoogle Scholar
  42. Folstein MF, Folstein SE, McHugh PR (1975) «Mini-mental state». A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189–198PubMedCrossRefGoogle Scholar
  43. Fossati R, Confalonieri C, Torri V et al. (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16(10):3439–3460PubMedGoogle Scholar
  44. Frasci G, Lorusso V, Panza N et al. (2000) Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 18(13):2529–2536PubMedGoogle Scholar
  45. Freyer G, Geay JF, Touzet S et al. (2005) Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. Ann Oncol 16(11):1795–1800PubMedCrossRefGoogle Scholar
  46. Früh M, Rolland E, Pignon JP et al. (2008) Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. J Clin Oncol 26(21):3573–3581PubMedCrossRefGoogle Scholar
  47. Gelman RS, Taylor SGT (1984) Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol 2(12):1404–1413PubMedGoogle Scholar
  48. Geyer CE, Forster J, Lindquist D et al. (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26):2733–2743PubMedCrossRefGoogle Scholar
  49. Giordano SH, Duan Z, Kuo YF, Hortobagyi GN, Goodwin JS (2006) Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 24(18):2750–2756PubMedCrossRefGoogle Scholar
  50. Giovanazzi-Bannon S, Rademaker A, Lai G, Benson AB 3rd (1994) Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: an Illinois Cancer Center study. J Clin Oncol 12(11):2447–2452PubMedGoogle Scholar
  51. Goldhirsch A, Gelman RS, Gelber RD, Castiglione M (1990) Treatment of breast cancer in elderly patients. Lancet 336(8714):564PubMedCrossRefGoogle Scholar
  52. Goldhirsch A, Coates AS, Gelber RD, Glick JH, Thürlimann B, Senn HJ, St Gallen Expert Panel Members (2006) First — select the target: better choice of adjuvant treatments for breast cancer patients. Ann Oncol 17(12):1772–1776PubMedCrossRefGoogle Scholar
  53. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ, 10th St. Gallen conference (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18(7):1133–1144PubMedCrossRefGoogle Scholar
  54. Goldstone AH, Burnett AK, Wheatley K et al. (2001) Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients:the results of the United Kingdom Medical Research Council AML11 trial. Blood, 2001. 98(5):1302–1311PubMedCrossRefGoogle Scholar
  55. Goodwin JS, Samet JM, Key CR, Humble C, Kutvirt D, Hunt C (1986) Stage at diagnosis of cancer varies with the age of the patient. J Am Geriatr Soc 34(1):20–26PubMedGoogle Scholar
  56. Gorner M, Spath-Schwalbe E (2008) Modern treatment options for elderly patients with multiple myeloma. Onkologie 31(6):335–342PubMedGoogle Scholar
  57. Haller DG, Catalano PJ, Macdonald JS, O’Rourke MA, Frontiera MS, Jackson DV, Mayer RJ (2005) Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 23(34):8671–8678PubMedCrossRefGoogle Scholar
  58. Harter P, du Bois A, Schade-Brittinger C et al. Non-enrolment of ovarian cancer patients in clinical trials: reasons and background. Ann Oncol 16(11):1801–1805Google Scholar
  59. Höffken K, Kolb G, Wedding U (2002) Geriatrische Onkologie. Springer, Berlin Heidelberg New YorkGoogle Scholar
  60. Honecker F, et al. (2009) Use of the Comprehensive Geriatric Assessment (CGA) in elderly patients (pts) with solid tumors to predict mortality. J Clin Oncol 27(15S):9549 (Abstract)Google Scholar
  61. Hulin C, Facon T, Rodon P et al. (2009) Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma:IFM 01/01 trial. J Clin Oncol 27(22):3664–3670PubMedCrossRefGoogle Scholar
  62. Hurwitz H, Fehrenbacher L, Novotny W et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342PubMedCrossRefGoogle Scholar
  63. Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS (1999) Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341(27):2061–2067PubMedCrossRefGoogle Scholar
  64. Albert US (Hrsg) (2008) Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. Zuckschwerdt, MünchenGoogle Scholar
  65. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354(8):809–820PubMedCrossRefGoogle Scholar
  66. Kabbinavar FF, Schulz J, McCleod M (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23(16):3697–3705PubMedCrossRefGoogle Scholar
  67. Kabbinavar FF, Hurwitz HI, Yi J, Sarkar S, Rosen O (2009) Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol 27(2):199–205PubMedCrossRefGoogle Scholar
  68. Kalbe E, Kessler J, Calabrese P, Smith R, Passmore AP, Brand M, Bullock R (2004) DemTect: a new, sensitive cognitive screening test to support the diagnosis of mild cognitive impairment and early dementia. Int J Geriatr Psychiatry 19(2):136–143PubMedCrossRefGoogle Scholar
  69. Karnofsky DA, Adelmann WH, Craver FL (1948) The use of nitrogen mustard in the palliative treatment of carcinoma. Cancer 1:634–656CrossRefGoogle Scholar
  70. Keating NL, Landrum MB, Klabunde CN et al. (2008) Adjuvant chemotherapy for stage III colon cancer: do physicians agree about the importance of patient age and comorbidity? J Clin Oncol 26(15):2532–2537PubMedCrossRefGoogle Scholar
  71. Kemeny MM, Peterson BL, Kornblith AB et al. (2003) Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol 21(12):2268–2275PubMedCrossRefGoogle Scholar
  72. Knauf WU, Lissichkov T, Aldaoud A et al. (2009) Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 27(26):4378–4384PubMedCrossRefGoogle Scholar
  73. Köhne CH, Folprecht G, Goldberg RM, Mitry E, Rougier P (2008) Chemotherapy in elderly patients with colorectal cancer. Oncologist 13(4):390–402PubMedCrossRefGoogle Scholar
  74. Kudoh S, Takeda K, Nakagawa K et al. (2006) Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer:results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 24(22):3657–3663PubMedCrossRefGoogle Scholar
  75. Lawton MP, Brody EM (1969) Assessment of older people:self-maintaining and instrumental activities of daily living. Gerontologist 9(3):179–186PubMedGoogle Scholar
  76. Lewis JH, Kilgore ML, Goldman DP et al. 2003) Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21(7):1383–1389PubMedCrossRefGoogle Scholar
  77. Lièvre A, Bachet JB, Boige V et al. (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26(3):374–379PubMedCrossRefGoogle Scholar
  78. Lynch TJ, Bell DW, Sordella R et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129–2139PubMedCrossRefGoogle Scholar
  79. Mahoney FI, Barthel DW (1965) Functional evaluation. Md State Med J 14:61–65PubMedGoogle Scholar
  80. Massie MJ (2004) Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr (32):57–71PubMedCrossRefGoogle Scholar
  81. Miller K, Wang M, Gralow J et al. (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26):2666–2676PubMedCrossRefGoogle Scholar
  82. Monfardini S, Sorio R, Boes GH, Kaye S, Serraino D (1995) Entry and evaluation of elderly patients in European Organization for Research and Treatment of Cancer (EORTC) newdrug-development studies. Cancer 76(2):333–338PubMedCrossRefGoogle Scholar
  83. Mor V, Laliberte L, Morris JN, Wiemann M (1984) The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting. Cancer 53(9):2002–2007PubMedCrossRefGoogle Scholar
  84. Muss HB, Berry DA, Cirrincione CT et al. (2009) Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 360(20):2055–2065PubMedCrossRefGoogle Scholar
  85. Neugut AI, Fleischauer AT, Sundararajan V, Mitra N, Heitjan DF, Jacobson JS, Grann VR (2002) Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: a population-based study. J Clin Oncol 20(11):2643–2650PubMedCrossRefGoogle Scholar
  86. Nikolaus T, Specht-Leible N, Bach M, Oster P, Schlierf G (1994) Social aspects in diagnosis and therapy of very elderly patients. Initial experiences with a newly developed questionnaire within the scope of geriatric assessment. Z Gerontol 27(4):240–245PubMedGoogle Scholar
  87. Osborne CK, Pippen J, Jones SE et al. (2002) Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20(16):3386–3395PubMedCrossRefGoogle Scholar
  88. Pallis AG, Gridelli C, Meerbeeck JP van et al. (2009) EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts’ opinion for the treatment of non-small-cell lung cancer in an elderly population. Ann Oncol(in print)Google Scholar
  89. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659–1672PubMedCrossRefGoogle Scholar
  90. Pignon JP, Tribodet H, Scagliotti GV et al. (2008) Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 26(21):3552–3559PubMedCrossRefGoogle Scholar
  91. Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH (2007) Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25(25):3808–3815PubMedCrossRefGoogle Scholar
  92. Podsiadlo D, Richardson S (1991) The timed «Up & Go»: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 39(2):142–148PubMedGoogle Scholar
  93. Rao AV, Hsieh F, Feussner JR, Cohen HJ (2005) Geriatric evaluation and management units in the care of the frail elderly cancer patient. J Gerontol A Biol Sci Med Sci 60(6):798–803PubMedGoogle Scholar
  94. Read WL, Tierney RM, Page NC, Costas I, Govindan R, Spitznagel EL, Piccirillo JF (2004) Differential prognostic impact of comorbidity. J Clin Oncol 22(15): 3099–3103PubMedCrossRefGoogle Scholar
  95. Rehse B, Pukrop R (2003) Effects of psychosocial interventions on quality of life in adult cancer patients: meta analysis of 37 published controlled outcome studies. Patient Educ Couns 50(2): 179–186PubMedGoogle Scholar
  96. Repetto L, Venturino A, Vercelli M et al. (1998) Performance status and comorbidity in elderly cancer patients compared with young patients with neoplasia and elderly patients without neoplastic conditions (see comments). Cancer 82(4): 760–765PubMedCrossRefGoogle Scholar
  97. Repetto L, Biganzoli L, Koehne CH, Luebbe AS, Soubeyran P, Tjan-Heijnen VC, Aapro MS (2003) EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur J Cancer 39(16): 2264–2272PubMedCrossRefGoogle Scholar
  98. Romond EH, Perez EA, Bryant J et al. (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16): 1673–1684PubMedCrossRefGoogle Scholar
  99. Samet J, Hunt WC, Key C, Humble CG, Goodwin JS (1986) Choice of cancer therapy varies with age of patient. Jama 255(24):3385–3390PubMedCrossRefGoogle Scholar
  100. Sargent DJ, Goldberg RM, Jacobson SD et al. (2001) A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345(15):1091–1097PubMedCrossRefGoogle Scholar
  101. Sargent DJ, Wieand HS, Haller DG et al. (2005) data from 20,898 patients on 18 randomized trials. J Clin Oncol, 2005. 23(34):8664–8670PubMedCrossRefGoogle Scholar
  102. Sargent DJ, Patiyil S, Yothers G et al. (2007) End points for colon cancer adjuvant trials:observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol 25(29):4569–4574PubMedCrossRefGoogle Scholar
  103. Sargent D, Sobrero A, Grothey A et al. (2009) Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 27(6):872–877PubMedCrossRefGoogle Scholar
  104. Schairer C, Mink PJ, Carroll L, Devesa SS (2004) Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst 96(17):1311–1321PubMedCrossRefGoogle Scholar
  105. Schmiegel W, Reinacher-Schick A, Arnold D et al. (2008) (Update S3-guideline «colorectal cancer» 2008). Z Gastroenterol 46(8):799–840PubMedCrossRefGoogle Scholar
  106. Schmoll HJ, Cartwright T, Tabernero J et al. (2007) Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 25(1):102–109PubMedCrossRefGoogle Scholar
  107. Schröder KE, Schwarzer R (1997) Bewältigungsressourcen. In: C. Tesch-Römer, C. Salewski, G. Schwarz (Eds) Psychologie der Bewältigung. Psychologie,: Weinheim, S. 174–195Google Scholar
  108. Slamon DJ, Leyland-Jones B, Shak S et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792PubMedCrossRefGoogle Scholar
  109. Sommer G, Fydrich T (1989) Unterstützung:Diagnostik, Konzepte, F-SOZU. Tübingen, Deutsche Gesellschaft für Verhaltenstherapie Statistisches Bundesamt (2010) http://www.destatis.de/jetspeed/portal/cms/Sites/destatis/Internet/DE/Content/Statistiken/Bevoelkerung/GeburtenSterbefaelle/Tabellen/Content100/SterbetafelDeutschland,property=file.xls. Gesehen 05.01.2010Google Scholar
  110. Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropol NJ (1995) Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 75(1):11–17PubMedCrossRefGoogle Scholar
  111. Strauß B, Berger U, Troschke J von, Brähler E (2004) Lehrbuch medizinische Psychologie und medizinische Soziologie. Hogrefe, GöttingenGoogle Scholar
  112. Stuck AE, Siu AL, Wieland GD, Adams J, Rubenstein LZ (1993) Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet 342(8878):1032–1036PubMedCrossRefGoogle Scholar
  113. Sundararajan V, Mitra N, Jacobson JS, Grann VR, Heitjan DF, Neugut AI (2002) Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with nodepositive colon cancer. Ann Intern Med 136(5):349–357PubMedGoogle Scholar
  114. The Elderly Lung Cancer Vinorelbine Italian Study Group (1999) Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 91(1):66–72CrossRefGoogle Scholar
  115. Tinetti ME (1986) Performance-oriented assessment of mobility problems in elderly patients. J Am Geriatr Soc 34(2):119–126PubMedGoogle Scholar
  116. Tol J, Koopman M, Cats A et al. (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360(6):563–572PubMedCrossRefGoogle Scholar
  117. Trimble EL, Carter CL, Cain D, Freidlin B, Ungerleider RS, Friedman MA (1994) Representation of older patients in cancer treatment trials. Cancer 74(7 Suppl):2208–2214PubMedCrossRefGoogle Scholar
  118. Turner NJ, Haward RA, Mulley GP, Selby PJ (1999) Cancer in old age — is it inadequately investigated and treated? BMJ 319(7205):309–312PubMedGoogle Scholar
  119. Twelves C, Wong A, Nowacki MP et al. 2005) Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352(26):2696–2704PubMedCrossRefGoogle Scholar
  120. Wagner AD, Wedding U (2009) Advances in the pharmacological treatment of gastro-oesophageal cancer. Drugs Aging 26(8):627–646PubMedCrossRefGoogle Scholar
  121. Watson M, McCarron J, Law M (1992) Anticipatory nausea and emesis, and psychological morbidity: assessment of prevalence among out-patients on mild to moderate chemotherapy regimens. Br J Cancer 66(5):862–866PubMedGoogle Scholar
  122. Watson YI, Arfken CL, Birge SJ (1993) Clock completion: an objective screening test for dementia. J Am Geriatr Soc 41(11):1235–1240PubMedGoogle Scholar
  123. Wedding U, Bokemeyer C, Meran JG (2004) Elderly patients with acute myeloid leukaemia: characteristics in biology, patients and treatment. Recommendations of the Working Group Geriatric Oncology of the German Society for Haematology and Oncology (DGHO), the Austrian Society for Haematology and Oncology (OGHO) and the German Society for Geriatrics (DGG). Onkologie 27(1):72–82PubMedCrossRefGoogle Scholar
  124. Wedding U, Höffken K, Friedrich C, Pientka L (2007a) Health services research and geriatrics: deficits and research approaches using the example of colorectal carcinoma and anaemia. Z Arztl Fortbild Qualitatssich 101(9):587–592PubMedGoogle Scholar
  125. Wedding U, Honecker F, Bokemeyer C, Pientka L, Höffken K (2007b) Tolerance to chemotherapy in elderly patients with cancer. Cancer Control 14(1):44–56PubMedGoogle Scholar
  126. Wedding U, Honecker F, Pienkta L, Höffken K (2007c) Klinische Studien und Patientregister für alte Patienten mit Krebserkrankungen. Onkologe 13(9):783–791CrossRefGoogle Scholar
  127. Wedding U, Röhrig B, Pientka L, Höffken K (2007d) Anaemiarelated impairment in quality of life in elderly cancer patients prior to chemotherapy. J Cancer Res Clin Oncol 133(5):279–286PubMedCrossRefGoogle Scholar
  128. Wedding, U., et al. (2008) Comprehensive Geriatric Assessment (CGA) in elderly patients with hematological neoplasia: CGA and not age predicts mortality — Results from in-GHO-Registry. Blood 112(11):1310 (Abstract)Google Scholar
  129. Wehling M (2008) Drug therapy in the elderly: too much or too little, what to do? A new assessment system: fit for the aged (FORTA). Dtsch Med Wochenschr 133(44):2289–2291PubMedCrossRefGoogle Scholar
  130. Wehling M (2009) Multimorbidity and polypharmacy: how to reduce the harmful drug load and yet add needed drugs in the elderly? Proposal of a new drug classification: fit for the aged. J Am Geriatr Soc 57(3):560–561PubMedCrossRefGoogle Scholar
  131. Wheatley-Price P, Ding K, Seymour L, Clark GM, Shepherd FA (2008) Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 26(14):2350–2357PubMedCrossRefGoogle Scholar
  132. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, Leirer VO (1982) Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 17(1):37–49PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  • Martin Wehling
    • 1
  • Heinrich Burkhardt
    • 2
  • Stefan Schwarz
    • 3
  • Lutz Frölich
    • 3
  • Ulrich Wedding
    • 4
  1. 1.Medizinische Fakultät Mannheim der Universität HeidelbergMannheim
  2. 2.Universitätsklinikum MannheimMannheim
  3. 3.Zentralinstitut für Seelische GesundheitMannheim
  4. 4.Klinik für Innere Medizin II Abteilung PalliativmedizinUniversitätsklinikum JenaJena

Personalised recommendations